Autopsy report · NCT04064697

Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy

“low of inclusions”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months before it started.
• Ran for about 2 years 10 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Sponsor type

University, hospital or other

Conditions

Ulcerative Colitis, Unspecified

Interventions

Valganciclovir

Participants

6

Sites

8

Countries

France

Trials that died the same way

• Tamsulosin for Urinary Retention in Hospitalized Older Women
  “low inclusion” (95% match in meaning)
• Pronostic Value of Endothelial Dysfunction in Heart Failure
  “Not enough inclusions” (79% match in meaning)
• Development of a Predictive Score for Local Complications of Femoral Bifurcation Surgery
  “lack of inclusions” (79% match in meaning)
• Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging
  “low inclusion rates” (79% match in meaning)
• Transfusion Effects in Myelodysplastic Patients: Limiting Exposure
  “Too few inclusions” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.